亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 香蕉AV久久一区二区三区 | 丰满人妻妇伦又伦精品国产 | 亚洲av无码乱码国产精品玩偶 | 国产乱伦少妇无码大黄AA片 | 免费午夜无码18禁无码影院 | 韩国二区亚洲av无码一区二区三区人 | 亚洲日韩高清在线亚洲专区 | 91亚洲观看在线欧美亚洲 | 亚洲成人高清无码在线观看 | 日日摸夜夜欧美一区二区 | 亚洲av无码一区二区三区天堂古代 | AV无码国产精品午夜A片 | 色欲av蜜臀一区二区三区多人 | 国产日韩欧美视频一区二 | 日日夜夜精品视频天天综合精品视频 | 99久久久精品综合网 | 三女一男做二2爱A片 | free性少妇饥渴xxⅹxxhd | 四虎国产精品免费久久影院 | 国产精品h片在线播放 | 日韩精品国产自在久久现线拍 | 波多野结衣视频免费观看 | 国产精品亚洲精品久久品 | 北条麻妃毛片在线视频 | 日韩欧美国产成人 | 精品人妻无码一区二区色欲aⅴ | 久久精品国产亚洲av大全 | av天堂电影网在线观看 | 久久久久99精品成人片牛 | 国产成人久久精品流白浆动态 | 日本又色又爽又黄又免费网站 | 亚洲国产成人精品无码区99 | 日本人妻仑乱少妇A级毛片潘金莲 | 精品日产一区二区三区 | 成人无码视频在线观看网站 | 一区二区乱子伦在线播放 | 美女裸胸不打马赛克 | 人人舔人人爱 | 久久精品亚洲精品国产欧美 | 色在线视频免费观看视频 | 国产中文字幕一 |